Open AccessWhat are the main factors affecting the outcome of tocilizumab therapy in COVID-19-induced cytokine release syndrome?
Author(s) -
Cansu Akleylek,
AUTHOR_ID,
Seray Gizem Gür,
İbrahim Halil Sever,
Safiye Koçulu Demir,
Esin Çevik,
Egemen Eken,
Zafer Gökkaya,
Yonca Çağatay,
Neslihan Yılmaz,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID
Publication year - 2022
Publication title -
european journal of rheumatology
Language(s) - English
Resource type - Journals
eISSN - 2147-9720
pISSN - 2148-4279
DOI - 10.5152/eurjrheum.2022.21010
Subject(s) - medicine , tocilizumab , hypoxemia , mechanical ventilation , cytokine storm , cytokine release syndrome , intensive care unit , cytokine , oxygen therapy , covid-19 , gastroenterology , disease , infectious disease (medical specialty)
Recommendations for the treatment of cytokine release syndrome/macrophage activation syndrome (MAS) associated with coronavirus disease-2019 (COVID-19) are still of poor quality. IL-6 is an important therapeutic target as a main mediator of cytokine storm. The aim of our study was to evaluate the tocilizumab (TCZ) efficacy and factors affecting the therapy outcome.